Rachel Kopper

LaunchCyte LLC (LaunchCyte) is a venture capital firm founded in 2000 by Tom A.Petzinger and Barbara Bailey Carryer. The firm is headquartered in Pittsburgh, Pennsylvania.

Crystalplex Corp. operates a biochemistry and diagnostics laboratory that specializes in nanotechnology for the life sciences industry. Its proprietary technology, SapphireTM QDs provides a stable crystal design, flexible polymer matrix morphology, and meets environmentally responsible yet demanding performance requirements for high-end consumer electronics applications such as liquid crystal display televisions, displays, and high-CRI architectural lighting. The company was founded by Thomas A. Petzinge Jr. in 2004 and is headquartered in Pittsburgh, PA.

Veran Medical Technologies, Inc. designs, develops, and markets soft tissue equipment. The firm's main focus is assisting physicians in the early diagnosis and treatment of lung cancer. The company was founded by Ben Heavrin, Bruce Lynskey, Jerome R. Edwards, and Evan Austill, Jr. in 2005 and is headquartered in St. Louis, MO.

Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA.

AEGEA Medical, Inc. develops technology that utilizes convective water vapor to treat menorrhagia. The firm focuses on the development of its proprietary and innovative water vapor treatment for abnormal uterine bleeding. It has vapor system delivers controlled, low-pressure natural water vapor to the uterine cavity to efficiently ablate the inner lining of the uterus. The company was founded by Paul M. Goeld in 2008 and is headquartered in Redwood City, CA.

Advanced Catheter Therapies, Inc. operates as an early stage research and development medical device company. It develops a catheter technologies targeting vascular disease including thrombosis, inflammation, occlusions and restenosis. The company was founded by C. Rex Teeslink, Paul J. Fitzpatrick, and Dirk V. Hoyns in 2008 and is headquartered in Chattanooga, TN.

Aerial BioPharma LLC operates as a biopharmaceutical company. It focuses on developing biologics and small molecules for conditions that are affected by processes in the Central Nervous System. The company was founded by Moise A. Khayrallah, stephen E. Butts and Gary Bream in January 2011 and is headquartered in Morrisville, NC.

National Investor Relations Institute operates as an association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents. The company was founded by DeWitt C. Morrill in 1969 and is headquartered in Alexandria, VA.

Life Sciences Pennsylvania (LSPA) is a trade association that represents various entities in the life sciences industry, including biotechnology, medical device, diagnostic, pharmaceutical, research, and investment companies, as well as service providers. The non-profit company is based in Wayne, PA and has subsidiaries in the United States. The organization unifies innovators in the state to make Pennsylvania a leader in the life sciences industry. Founded in 1989, LSPA aims to create a business and public policy environment that encourages and incentivizes the diverse life sciences economy in Pennsylvania. Christopher P. Molineaux has been the CEO of the company since 2009.

BioStable Science & Engineering, Inc. engagses in the develop of products for the treatment of cardiovascular disease. It covers areas of product development including quality systems, design, engineering, prototyping and pilot production, in-vitro and in-vivo testing, manufacturing, global regulatory relationships, clinical product validation, market launch, and distribution. The firm provides a competitive edge by minimizing time to market for cost effective medical devices that deliver improved clinical outcomes. The company was founded by Al Alan Beavan, Charles D. Griffin, Douglas Charles Frank, Don James, J. Scott Rankin and Rusty Phillips in 2008 and is headquartered in Austin, TX.

Part of Pediatrix Medical Group, Inc., Regional Obstetric Consultants provides healthcare services. The company is based in Jacksonville, FL. The company was founded by C. David Adair. Regional Obstetric Consultants was acquired by Pediatrix Medical Group, Inc. on May 26, 2009.

Glenveigh Medical LLC develops drugs and devices to prevent the causes of premature births. Its products include Ebb, a tamponade solution for postpartum hemorrhage; Jetty, a solution for episiotomy and vaginal laceration repair; and Beacon, a fetal monitor. The company was founded by C. David Adair in 2004 and is headquartered in Chattanooga, TN.

The King's Fund organizes healthcare conferences and other events. The company was founded in 1897 and is headquartered in London, the United Kingdom.

Perspectum Ltd. provides technology solutions for diagnosing and staging liver disease. The company was founded by Rajarshi Banerjee, Stefan Karl Neubauer, Matthew David Robson, Alastair Cavanagh, James Hugh Charteris Mallinson and John Michael Brady on September 18, 2012 and is headquartered in Oxford, the United Kindgom.

Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom.

NX Prenatal, Inc. is amolecular diagnostics company, which engages in the development of diagnostic assays for adverse pregnancy conditions such as preterm birth. The company was founded by Gail S. Page and Brian D. Brohman and is headquartered in Louisville, KY.

Solas BioVentures (mayfield) LLC (Solas BioVentures) is a venture capital firm founded in 2012 by David Adair and Mark Hackett JD. The firm is headquartered in Chattanooga, Tennessee.

PlaqueTec Ltd. develops a liquid biopsy system platform technology that provides unparalleled resolution of the biological processes that cause coronary artery disease. The firm’s Liquid Biopsy System addresses the underlying biomarker collection problems preventing advances in CAD research. The company was founded by Stephen Blatcher in 2000 and is headquartered in Cambridge, the United Kingdom.

Elira, Inc. develops a system to suppress appetite and assist diet adherence. The company was founded by John Faul in 2015 and is headquartered in St. Louis, MO.

Biothera Pharmaceutical, Inc. operates as a biotechnology company. It develops Imprime PGG, a novel dectin receptor agonist that reverses tumor-mediated immunosuppression while promoting antigen presentation to drive T cell activation. The company was founded in 1997 and is headquartered in Roseville, MN.

Arrivo Management LLC is a biopharmaceutical company. It develops biologics and small molecules to improve patient lives. The company was founded by Steve Butts, Bill Wofford, Michael Ackermann and Jed Black on July 9, 2015 and is headquartered in Morrisville, NC.

Part of Harrow, Inc., Mayfield Pharmaceuticals, Inc. is a company that manufactures pharmaceutical products. The company is based in Las Vegas, NV. The CEO of the company is Melissa Bradford-Klug.

EirSystems, Inc. develops an e-Prescribing portal. It offers P.A.G.R. Prescriptions, advanced platform that will allow physicians and pharmacists to utilize built-in tools that make the prescribing process simpler, safer, and more efficient. The company was founded by Tyler Seaberg and Ryan Seaberg and is headquartered in Chattanooga, TN.

Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.

Noxsudor Therapeutics Ltd. manufactures capsules that control sweating.

Intershunt Technologies, Inc. is a medical device company based in Plymouth, MN. The company is developing a proprietary catheter system that allows for the capture and excision of tissue from the interatrial septum. This results in a left to right atrial shunt that off-loads elevated left atrial pressure, reducing symptoms in heart failure patients. The mechanical system is designed for safety and ease of use and is the only interatrial shunting device that requires no implant and no energy. The company was founded by Gil Vardi and the CEO is Harlee L. Sorkin.

RYSE Asset Management LLP (RYSE) is a venture capital firm founded in 2010 by Atique Mirza. The firm is headquartered in London, the United Kingdom.

The Conduit Connect Ltd. is a private membership platform for high net worth, sophisticated, and professional impact investors. The company is based in London, UK. The British company connects founders who are building scalable, for-profit, impact-driven businesses to capital and expert resources. The company source and connects the most promising high growth impact investing opportunities to mission-aligned investors. The company was founded in 2018, and the CEO is Eva-Maria Dimitriadis.

Perspectum Group Plc engages in the sale of diagnostic products via a software-as-a-medical device platform. Its products combine expertise in image formation, magnetic resonance image analysis and artificial intelligence to support healthcare provider diagnosis, treatment decision-making, and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies and cancer, and determine whether the patient is responding to therapy. Its products include Liver MultiScan, MRCP+, Hepatica, and CoverScan MD. The company was founded by Matthew Robson on June 10, 2021 and is headquartered in Oxford, the United Kingdom.

Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials.